August 14, 2014
A Georgia federal judge is refusing to dismiss a shareholder class action against MiMedx Group Inc. over statements that its scar-minimizing injectables weren't subject to normal FDA regulation, saying Wednesday that a full stock-price rebound doesn't necessarily mean the plaintiffs can't show they experienced losses.